5 results on '"Englbrecht C"'
Search Results
2. Eszopiclone for insomnia.
- Author
-
Rösner S, Englbrecht C, Wehrle R, Hajak G, and Soyka M
- Subjects
- Adult, Aged, Aged, 80 and over, Humans, Middle Aged, Randomized Controlled Trials as Topic, Time Factors, Treatment Outcome, Eszopiclone therapeutic use, Hypnotics and Sedatives therapeutic use, Sleep Initiation and Maintenance Disorders drug therapy
- Abstract
Background: Insomnia is a major public health issue affecting between 6% to 10% of the adult population in Western countries. Eszopiclone is a hypnotic drug belonging to a newer group of hypnotic agents, known as new generation hypnotics, which was marketed as being just as effective as benzodiazepines for this condition, while being safer and having a lower risk for abuse and dependence. It is the aim of the review to integrate evidence from randomised controlled trials and to draw conclusions on eszopiclone's efficacy and safety profile, while taking methodological features and bias risks into consideration., Objectives: To assess the efficacy and safety of eszopiclone for the treatment of insomnia compared to placebo or active control., Search Methods: We searched the Cochrane Central Register of Controlled trials (CENTRAL), MEDLINE, Embase, PsycINFO, PSYNDEX and registry databases (WHO trials portal, ClinicalTrials.gov) with results incorporated from searches to 10 February 2016. To identify trials not registered in electronic databases, we contacted key informants and searched reference lists of identified studies. We ran an update search (21 February 2018) and have placed studies of interest in awaiting classification/ongoing studies. These will be incorporated into the next version of the review, as appropriate., Selection Criteria: Parallel group randomised controlled trials (RCTs) comparing eszopiclone with either placebo or active control were included in the review. Participants were adults with insomnia, as diagnosed with a standardised diagnostic system, including primary insomnia and comorbid insomnia., Data Collection and Analysis: Two authors independently extracted outcome data; one reviewer assessed trial quality and the second author cross-checked it., Main Results: A total of 14 RCTs, with 4732 participants, were included in this review covering short-term (≤ 4 weeks; 6 studies), medium-term (> 4 weeks ≤ 6 months; 6 studies) and long-term treatment (> 6 months; 2 studies) with eszopiclone. Most RCTs included in the review included participants aged between 18 and 64 years, three RCTs only included elderly participants (64 to 85 years) and one RCT included participants with a broader age range (35 to 85 years). Seven studies considered primary insomnia; the remaining studies considered secondary insomnia comorbid with depression (2), generalised anxiety (1), back pain (1), Parkinson's disease (1), rheumatoid arthritis (1) and menopausal transition (1).Meta-analytic integrations of participant-reported data on sleep efficacy outcomes demonstrated better results for eszopiclone compared to placebo: a 12-minute decrease of sleep onset latency (mean difference (MD) -11.94 min, 95% confidence interval (CI) -16.03 to -7.86; 9 studies, 2890 participants, moderate quality evidence), a 17-minute decrease of wake time after sleep onset (MD -17.02 min, 95% CI -24.89 to -9.15; 8 studies, 2295 participants, moderate quality evidence) and a 28-minute increase of total sleep time (MD 27.70 min, 95% CI 20.30 to 35.09; 10 studies, 2965 participants, moderate quality evidence). There were no significant changes from baseline to the first three nights after drug discontinuation for sleep onset latency (MD 17.00 min, 95% CI -4.29 to 38.29; 1 study, 291 participants, low quality evidence) and wake time after sleep onset (MD -6.71 min, 95% CI -21.25 to 7.83; 1 study, 291 participants, low quality evidence). Adverse events during treatment that were documented more frequently under eszopiclone compared to placebo included unpleasant taste (risk difference (RD) 0.18, 95% CI 0.14 to 0.21; 9 studies, 3787 participants), dry mouth (RD 0.04, 95% CI 0.02 to 0.06; 6 studies, 2802 participants), somnolence (RD 0.04, 95% CI 0.02 to 0.06; 8 studies, 3532 participants) and dizziness (RD 0.03, 95% CI 0.01 to 0.05; 7 studies, 2933 participants). According to the GRADE criteria, evidence was rated as being of moderate quality for sleep efficacy outcomes and adverse events and of low quality for rebound effects and next-day functioning., Authors' Conclusions: Eszopiclone appears to be an efficient drug with moderate effects on sleep onset and maintenance. There was no or little evidence of harm if taken as recommended. However, as certain patient subgroups were underrepresented in RCTs included in the review, findings might not have displayed the entire spectrum of possible adverse events. Further, increased caution is required in elderly individuals with cognitive and motor impairments and individuals who are at increased risk of using eszopiclone in a non-recommended way.
- Published
- 2018
- Full Text
- View/download PDF
3. Extensive alterations of the whole-blood transcriptome are associated with body mass index: results of an mRNA profiling study involving two large population-based cohorts.
- Author
-
Homuth G, Wahl S, Müller C, Schurmann C, Mäder U, Blankenberg S, Carstensen M, Dörr M, Endlich K, Englbrecht C, Felix SB, Gieger C, Grallert H, Herder C, Illig T, Kruppa J, Marzi CS, Mayerle J, Meitinger T, Metspalu A, Nauck M, Peters A, Rathmann W, Reinmaa E, Rettig R, Roden M, Schillert A, Schramm K, Steil L, Strauch K, Teumer A, Völzke H, Wallaschofski H, Wild PS, Ziegler A, Völker U, Prokisch H, and Zeller T
- Subjects
- Aged, Aged, 80 and over, Cohort Studies, Female, Humans, Insulin metabolism, Male, Middle Aged, Oxidative Stress genetics, RNA, Messenger genetics, Reactive Oxygen Species metabolism, Reticulocytes metabolism, Signal Transduction genetics, Blood metabolism, Body Mass Index, Gene Expression Profiling
- Abstract
Background: Obesity, defined as pathologically increased body mass index (BMI), is strongly related to an increased risk for numerous common cardiovascular and metabolic diseases. It is particularly associated with insulin resistance, hyperglycemia, and systemic oxidative stress and represents the most important risk factor for type 2 diabetes (T2D). However, the pathophysiological mechanisms underlying these associations are still not completely understood. Therefore, in order to identify potentially disease-relevant BMI-associated gene expression signatures, a transcriptome-wide association study (TWAS) on BMI was performed., Methods: Whole-blood mRNA levels determined by array-based transcriptional profiling were correlated with BMI in two large independent population-based cohort studies (KORA F4 and SHIP-TREND) comprising a total of 1977 individuals., Results: Extensive alterations of the whole-blood transcriptome were associated with BMI: More than 3500 transcripts exhibited significant positive or negative BMI-correlation. Three major whole-blood gene expression signatures associated with increased BMI were identified. The three signatures suggested: i) a ratio shift from mature erythrocytes towards reticulocytes, ii) decreased expression of several genes essentially involved in the transmission and amplification of the insulin signal, and iii) reduced expression of several key genes involved in the defence against reactive oxygen species (ROS)., Conclusions: Whereas the first signature confirms published results, the other two provide possible mechanistic explanations for well-known epidemiological findings under conditions of increased BMI, namely attenuated insulin signaling and increased oxidative stress. The putatively causative BMI-dependent down-regulation of the expression of numerous genes on the mRNA level represents a novel finding. BMI-associated negative transcriptional regulation of insulin signaling and oxidative stress management provide new insights into the pathogenesis of metabolic syndrome and T2D.
- Published
- 2015
- Full Text
- View/download PDF
4. Reconstitution of the human U snRNP assembly machinery reveals stepwise Sm protein organization.
- Author
-
Neuenkirchen N, Englbrecht C, Ohmer J, Ziegenhals T, Chari A, and Fischer U
- Subjects
- Animals, DEAD Box Protein 20 genetics, DEAD Box Protein 20 metabolism, Humans, Minor Histocompatibility Antigens, Muscular Atrophy, Spinal genetics, Mutation, Protein-Arginine N-Methyltransferases genetics, Protein-Arginine N-Methyltransferases metabolism, RNA, Small Nuclear metabolism, Recombinant Proteins genetics, Recombinant Proteins metabolism, Ribonucleoproteins, Small Nuclear genetics, SMN Complex Proteins genetics, Ribonucleoproteins, Small Nuclear metabolism, SMN Complex Proteins metabolism
- Abstract
The assembly of spliceosomal U snRNPs depends on the coordinated action of PRMT5 and SMN complexes in vivo. These trans-acting factors enable the faithful delivery of seven Sm proteins onto snRNA and the formation of the common core of snRNPs. To gain mechanistic insight into their mode of action, we reconstituted the assembly machinery from recombinant sources. We uncover a stepwise and ordered formation of distinct Sm protein complexes on the PRMT5 complex, which is facilitated by the assembly chaperone pICln. Upon completion, the formed pICln-Sm units are displaced by new pICln-Sm protein substrates and transferred onto the SMN complex. The latter acts as a Brownian machine that couples spontaneous conformational changes driven by thermal energy to prevent mis-assembly and to ensure the transfer of Sm proteins to cognate RNA. Investigation of mutant SMN complexes provided insight into the contribution of individual proteins to these activities. The biochemical reconstitution presented here provides a basis for a detailed molecular dissection of the U snRNP assembly reaction., (© 2015 The Authors.)
- Published
- 2015
- Full Text
- View/download PDF
5. Evaluation of BG-Sentinel Trap as a Management Tool to Reduce Aedes albopictus Nuisance in an Urban Environment in Italy.
- Author
-
Englbrecht C, Gordon S, Venturelli C, Rose A, and Geier M
- Subjects
- Animals, Cities, Italy, Aedes, Mosquito Control methods
- Abstract
Since its introduction and establishment in Italy during the early 1990s, the Asian tiger mosquito, Aedes albopictus, has spread over large parts of Italy and other Mediterranean countries. Aedes albopictus is both a nuisance and a competent vector for various arthropod-borne pathogens. Although efficient traps for Ae. albopictus exist and are used for population monitoring, their use as a control tool has not yet been studied. We evaluated Biogents BG-Sentinel mosquito traps, used with the BG Lure, as control tools in northern Italy. The trial was performed as a controlled experiment in which 3 intervention sites, equipped with 7 or 8 BG-Sentinel traps each, were matched with 3 comparable control sites. Trap density ranged from 1 trap per 150 m² to 1 per 350 m². Mosquito populations were monitored at both the intervention and control sites with weekly human landing collections (HLC) and ovitraps. Between 64% and 87% fewer Ae. albopictus individuals were collected by HLC at the intervention sites with the BG-Sentinel mosquito traps, as compared to the untreated control sites. These results indicate that the sustained use and proper placement of efficient mosquito traps can significantly reduce Ae. albopictus biting pressure.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.